Corporate Profile

Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected by mid-November 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Relations

News Releases

25 Aug '21
GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer’s pathologies SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 25, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s